367 related articles for article (PubMed ID: 32986841)
21. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
Droog M; Nevedomskaya E; Kim Y; Severson T; Flach KD; Opdam M; Schuurman K; Gradowska P; Hauptmann M; Dackus G; Hollema H; Mourits M; Nederlof P; van Boven H; Linn SC; Wessels L; van Leeuwen FE; Zwart W
Cancer Res; 2016 Jul; 76(13):3773-84. PubMed ID: 27197147
[TBL] [Abstract][Full Text] [Related]
22. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
[TBL] [Abstract][Full Text] [Related]
23. TRIM11 promotes breast cancer cell proliferation by stabilizing estrogen receptor α.
Tang J; Luo Y; Tian Z; Liao X; Cui Q; Yang Q; Wu G
Neoplasia; 2020 Sep; 22(9):343-351. PubMed ID: 32599554
[TBL] [Abstract][Full Text] [Related]
24. Arsenic‑induced BRCA1 CpG promoter methylation is associated with the downregulation of ERα and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
Selmin OI; Donovan MG; Skovan B; Paine-Murieta GD; Romagnolo DF
Int J Oncol; 2019 Mar; 54(3):869-878. PubMed ID: 30664189
[TBL] [Abstract][Full Text] [Related]
25. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
26. SGK3 sustains ERα signaling and drives acquired aromatase inhibitor resistance through maintaining endoplasmic reticulum homeostasis.
Wang Y; Zhou D; Phung S; Warden C; Rashid R; Chan N; Chen S
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1500-E1508. PubMed ID: 28174265
[TBL] [Abstract][Full Text] [Related]
27. Gene expression signature of estrogen receptor alpha status in breast cancer.
Abba MC; Hu Y; Sun H; Drake JA; Gaddis S; Baggerly K; Sahin A; Aldaz CM
BMC Genomics; 2005 Mar; 6():37. PubMed ID: 15762987
[TBL] [Abstract][Full Text] [Related]
28. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
29. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
30. Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer.
Du J; Zhou N; Liu H; Jiang F; Wang Y; Hu C; Qi H; Zhong C; Wang X; Li Z
PLoS One; 2012; 7(4):e35957. PubMed ID: 22558281
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
Nassa G; Salvati A; Tarallo R; Gigantino V; Alexandrova E; Memoli D; Sellitto A; Rizzo F; Malanga D; Mirante T; Morelli E; Nees M; Åkerfelt M; Kangaspeska S; Nyman TA; Milanesi L; Giurato G; Weisz A
Sci Adv; 2019 Feb; 5(2):eaav5590. PubMed ID: 30775443
[TBL] [Abstract][Full Text] [Related]
32. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
[TBL] [Abstract][Full Text] [Related]
33. Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor alpha and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts.
Bouclier C; Marsaud V; Bawa O; Nicolas V; Moine L; Opolon P; Renoir JM
Breast Cancer Res Treat; 2010 Jul; 122(1):145-58. PubMed ID: 19771505
[TBL] [Abstract][Full Text] [Related]
34. The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer.
Magnani L; Patten DK; Nguyen VT; Hong SP; Steel JH; Patel N; Lombardo Y; Faronato M; Gomes AR; Woodley L; Page K; Guttery D; Primrose L; Fernandez Garcia D; Shaw J; Viola P; Green A; Nolan C; Ellis IO; Rakha EA; Shousha S; Lam EW; Győrffy B; Lupien M; Coombes RC
Oncotarget; 2015 Sep; 6(26):21878-91. PubMed ID: 26215677
[TBL] [Abstract][Full Text] [Related]
35. A hidden Markov model to identify combinatorial epigenetic regulation patterns for estrogen receptor α target genes.
Bonneville R; Jin VX
Bioinformatics; 2013 Jan; 29(1):22-8. PubMed ID: 23104890
[TBL] [Abstract][Full Text] [Related]
36. ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.
Zhang J; Zhou C; Jiang H; Liang L; Shi W; Zhang Q; Sun P; Xiang R; Wang Y; Yang S
Cell Death Dis; 2017 Apr; 8(4):e2732. PubMed ID: 28383555
[TBL] [Abstract][Full Text] [Related]
37. KLF17 attenuates estrogen receptor α-mediated signaling by impeding ERα function on chromatin and determines response to endocrine therapy.
Ali A; Ielciu I; Alkreathy HM; Khan AA
Biochim Biophys Acta; 2016 Jul; 1859(7):883-95. PubMed ID: 27107895
[TBL] [Abstract][Full Text] [Related]
38. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity.
Peterson TJ; Karmakar S; Pace MC; Gao T; Smith CL
Mol Cell Biol; 2007 Sep; 27(17):5933-48. PubMed ID: 17591692
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer.
Morotti M; Bridges E; Valli A; Choudhry H; Sheldon H; Wigfield S; Gray N; Zois CE; Grimm F; Jones D; Teoh EJ; Cheng WC; Lord S; Anastasiou D; Haider S; McIntyre A; Goberdhan DCI; Buffa F; Harris AL
Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12452-12461. PubMed ID: 31152137
[TBL] [Abstract][Full Text] [Related]
40. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]